Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge Infection

The sudden emergence of SARS-CoV-2 demonstrates the need for new vaccines that rapidly protect in the case of an emergency. In this study, we developed a recombinant MVA vaccine co-expressing SARS-CoV-2 prefusion-stabilized spike protein (ST) and SARS-CoV-2 nucleoprotein (N, MVA-SARS-2-ST/N) as an a...

Full description

Saved in:

Bibliographic Details
Published in:	Viruses Vol. 16; no. 3; p. 417
Main Authors:	Clever, Sabrina, Limpinsel, Leonard, Meyer Zu Natrup, Christian, Schünemann, Lisa-Marie, Beythien, Georg, Rosiak, Malgorzata, Hülskötter, Kirsten, Gregor, Katharina Manuela, Tuchel, Tamara, Kalodimou, Georgia, Freudenstein, Astrid, Kumar, Satendra, Baumgärtner, Wolfgang, Sutter, Gerd, Tscherne, Alina, Volz, Asisa
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI AG 01-03-2024 MDPI
Subjects:	Amino acids Animals Antibodies Antibodies, Neutralizing Antibodies, Viral Antigens Cell culture COVID-19 - prevention & control COVID-19 Vaccines Disease transmission Evaluation gamma-Globulins Genomes Humans Immunogenicity Infections Influenza K18-hACE2 mice Licenses Lymphocytes T Melphalan Mice multivalent vaccine Pandemics Pathogens poxvirus Proteins Public health Public health administration Respiration SARS-CoV-2 SARS-CoV-2 - genetics Severe acute respiratory syndrome coronavirus 2 Spike Glycoprotein, Coronavirus - genetics Spike protein Vaccination Vaccines, DNA Viral Vaccines Viruses Germany poxvirus SARS-CoV-2 K18-hACE2 mice multivalent vaccine
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The sudden emergence of SARS-CoV-2 demonstrates the need for new vaccines that rapidly protect in the case of an emergency. In this study, we developed a recombinant MVA vaccine co-expressing SARS-CoV-2 prefusion-stabilized spike protein (ST) and SARS-CoV-2 nucleoprotein (N, MVA-SARS-2-ST/N) as an approach to further improve vaccine-induced immunogenicity and efficacy. Single MVA-SARS-2-ST/N vaccination in K18-hACE2 mice induced robust protection against lethal respiratory SARS-CoV-2 challenge infection 28 days later. The protective outcome of MVA-SARS-2-ST/N vaccination correlated with the activation of SARS-CoV-2-neutralizing antibodies (nABs) and substantial amounts of SARS-CoV-2-specific T cells especially in the lung of MVA-SARS-2-ST/N-vaccinated mice. Emergency vaccination with MVA-SARS-2-ST/N just 2 days before lethal SARS-CoV-2 challenge infection resulted in a delayed onset of clinical disease outcome in these mice and increased titers of nAB or SARS-CoV-2-specific T cells in the spleen and lung. These data highlight the potential of a multivalent COVID-19 vaccine co-expressing S- and N-protein, which further contributes to the development of rapidly protective vaccination strategies against emerging pathogens.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Passed away during the final stages of completion of this manuscript.
ISSN:	1999-4915 1999-4915
DOI:	10.3390/v16030417